David Chang and Arie Belldregun are trying to disrupt the CAR-T space, but analysts say they face an uphill battle in a crowded field (Jeff Rumans)
#ASH20 saw a BCMA brawl. Who's still standing? And who got knocked out for good?
Can too much success be a bad thing?
Probably not for patients, but for drug companies the overwhelming success of BCMA-targeting therapies is probably going …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
